Saule Serikova

As trust shifts from a stated value to an operating condition, pharmaceutical leaders face new expectations for how credibility is built, governed and sustained under continuous scrutiny.

The core building blocks of trust must be operationalized for pharma companies to strengthen their social contract, deliver business value, and improve patients’ quality of life.

Exploring new character benchmarks for today’s pharma executives, and whether they have the transformational traits to lead through change.

Outlining the new leadership and C-level roles of tomorrow needed to take on the disruption event on pharma's horizon.

How a strong corporate board can help ignite success in these regions.

Biopharma’s diversity commitment remains a work in progress but the benefits-in measurable ROI-are increasingly clear.